The management of hirsutism

Abstract

Many women present in general practice with the complaint of excessive hair growth on the face, chest or limbs. This article aims to cover the normal physiology of hair growth, how to define excessive hair growth in a woman, and when it is essential to refer a patient for urgent secondary care advice and further management.

Get full access to this article

View all access options for this article.

References

Batukan

Muderris

(2006) Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertility and Sterility 85(2): 436–440. DOI: 10.1016/j.fertnstert.2005.07.1311.

Bode

Seehusen

Baird

(2012) Hirsutism in women. American Family Physician 85(4): 373–380. Available at: www.aafp.org/afp/2012/0215/p373.pdf (accessed 15 April 2019).

British Medical Association and Royal Pharmaceutical Society of Great (2018) Britain British National Formulary 75th edition, London: British Medical Association and Royal Pharmaceutical Society of Great Britain.

Buffoli

Rinaldi

Labanca

et al. (2014) The human hair: From anatomy to physiology. International Journal of Dermatology 53(3): 331–341. DOI: 10.1111/ijd.12362.

Escobar-Morreale

Carmina

Dewailly

et al. (2012) Epidemiology, diagnosis and management of hirsutism: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 18(2): 146–170. DOI: 10.1093/humupd/dmr042.

Fitzgerald

Elstein

Spona

(1999) Effect of age on the response of the hypothalamo-pituitary-ovarian axis to a combined oral contraceptive. Fertility and Sterility 71(6): 1079–1084. DOI: 10.1016/S0015-0282(99)00146-6.

Food and Drug Administration (2010) Removing hair safely. Available at: www.fda.gov/ForConsumers/ConsumerUpdates/ucm048995.htm (accessed 24 December 2018).

Franks

(2012) The investigation and management of hirsutism. Journal of Family Planning and Reproductive Health Care 38(3): 182–186. DOI: 10.1136/jfprhc-2011-100175.

Koulouri

Conway

(2009) Management of hirsutism. British Medical Journal 27: 338 b847. DOI: 10.1136/bmj.b847.

10.

Kumar

St John

Devendra

(2009) Hirsutism. British Medical Journal 28: 339 b3090. DOI: 10.1136/bmj.b3090.

11.

Martin

Chang

Ehrmann

et al. (2008) Evaluation and treatment of hirsutism in premenopausal women. American Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 93(4): 1105–1120. DOI: 10.1210/jc.2007-2437.

12.

MHRA (2008) Cyproterone acetate with ethinylestradiol (co-cyprindiol): Recommended duration of use. Drug Safety Update 1(9): 4.

13.

MHRA (2011) Yasmin: Risk of venous thromboembolism higher than levonorgestrel-containing pills. Drug Safety Update 4(11): A2. Available at: www.gov.uk/drug-safety-update/yasmin-risk-of-venous-thromboembolism-higher-than-levonorgestrel-containing-pills (accessed 15 April 2019).

14.

MHRA (2013) Cyproterone acetate with ethinylestradiol (co-cyprindiol). Balance of benefits and risks remains positive. Updated prescribing advice provided. Drug Safety Update 6(11): A3 Available at: www.gov.uk/drug-safety-update/cyproterone-acetate-with-ethinylestradiol-co-cyprindiol-balance-of-benefits-and-risks-remains-positive (accessed 15 April 2019).

15.

NHS England (2013) Interim clinical commissioning policy: Hair removal (including electrolysis and laser therapy) agreed November 2013. Available at: www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/11/N-SC017.pdf (accessed 12 December 2018).

16.

NICE (2013) Clinical knowledge summaries: Polycystic ovary syndrome. Available at: https://cks.nice.org.uk/polycystic-ovary-syndrome (accessed 3 September 2018).

17.

NICE (2014) Clinical knowledge summaries: Hirsutism. Available at: https://cks.nice.org.uk/hirsutism (accessed 3 September 2018).

18.

NICE (2017a) Referral guidelines for suspected cancer. Available at: www.nice.org.uk/guidance/ng12/chapter/Update-information (accessed 3 September 2018).

19.

NICE (2017b) Clinical knowledge summaries: Obesity. Available at: https://cks.nice.org.uk/obesity (accessed 3 September 2018).

20.

Pasquali

Gambineri

(2014) Therapy in endocrine disease: Treatment of hirsutism in the polycystic ovary syndrome. European Journal of Endocrinology 170: R75–R90. DOI: 10.1530/EJE.13-0585.

21.

RCGP. Clinical module 3.06: Women’s health. Available at: www.rcgp.org.uk/training-exams/training/gp-curriculum-overview/online-curriculum/caring-for-the-whole-person/3-06-womens-health.aspx (accessed 23 August 2018).

22.

RCGP. Clinical module 3.21: Care of people with skin problems. Available at: www.rcgp.org.uk/training-exams/training/gp-curriculum-overview/online-curriculum/applying-clinical-knowledge-section-2/3-21-skin-problems.aspx (accessed 3 September 2018).

23.

RCOG (2014) Long-term consequences of polycystic ovary syndrome. Available at: www.rcog.org.uk/globalassets/documents/guidelines/gtg_33.pdf (accessed 3 September 2018).

24.

Rosenfield

(2008) What every physician should know about polycystic ovary syndrome. Dermatologic Therapy 21: 354–361. DOI: 10.1111/j.1529-8019.2008.00217.

25.

Rosenfield

Ehrmann

(2016) The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrinology Review 37(5): 467–520.

26.

Sathyapalan

Atkin

(2009) Investigating hirsutism. British Medical Journal 28(338): b912 DOI: 10.1136/bmj.b912.

27.

Unluhizarci

Karaca

Kelestimur

(2013) Hirsutism. From diagnosis to use of antiandrogens. Frontiers of Hormones Research 40: 103–114. DOI: 10.1159/000341822.

28.

Yildiz

Bolour

Woods

et al. (2010) Visually scoring hirsutism update. Human Reproduction 16(1): 51–64. DOI: 10.1093/humupd/dmp024.